Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)
NAMS Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
279.50%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
46.80%
NAMS Stock Analysis
NAMS
PE Ratio:
NAMS
PEG Ratio:
Not Available
NAMS
Forward EPS Growth (12 month):
0.00%
NAMS
PS Ratio:
144.7
NAMS
PSG Ratio:
0.4
NAMS
Forward Revenue Growth (12 month):
400.00%
NAMS Articles
No data was found